skip to main content
Show Results with:

Comparable Outcomes of Allogeneic Peripheral Blood versus Bone Marrow Hematopoietic Stem Cell Transplantation in Major Thalassemia: A Multivariate Long-Term Cohort Analysis

Ghavamzadeh, Ardeshir et al.

Biology of blood and marrow transplantation. Volume 25:Number 2 (2019, February); pp 307-312 -- Elsevier Inc

Online access

  • Title:
    Comparable Outcomes of Allogeneic Peripheral Blood versus Bone Marrow Hematopoietic Stem Cell Transplantation in Major Thalassemia: A Multivariate Long-Term Cohort Analysis
  • Author: Ghavamzadeh, Ardeshir;
    Kasaeian, Amir;
    Rostami, Tahereh;
    Kiumarsi, Azadeh
  • Found In: Biology of blood and marrow transplantation. Volume 25:Number 2 (2019, February); pp 307-312
  • Journal Title: Biology of blood and marrow transplantation
  • Subjects: Bone Marrow Transplantation--Periodicals; Hematopoietic Stem Cell Transplantation--Periodicals; Bone marrow--Transplantation--Periodicals; Hematopoietic stem cells--Transplantation--Periodicals; Thalassemia major--Allogeneic transplantation--Bone marrow transplants--Peripheral blood transplants; Electronic journals; Dewey: 617.4410592
  • Rights: Licensed
  • Publication Details: Elsevier Inc
  • Abstract: Highlights The aim of this study was to evaluate the pros and cons of using peripheral blood instead of bone marrow as the graft source in thalassemia transplantation. The survival advantage for bone marrow compared with peripheral blood was not significant. Rejection incidence was significantly lower in patients who used peripheral blood as their graft source. Acute and chronic graft-versus-host disease were more frequent in peripheral blood transplants, but the difference was not statistically significant. Peripheral blood could be the preferred stem cell source in patients undergoing allogeneic stem cell transplantation for thalassemia. Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) currently is the only available curative option for transfusion-dependent thalassemia. Peripheral blood is a more convenient source for HSCT in comparison with bone marrow. Information about the relative success of transplantation with these 2 graft sources would help physicians and patients choose between them. The aim of this study was to evaluate the pros and cons of using peripheral blood instead of bone marrow as the graft source in thalassemia transplantation. We analyzed the transplant results of 567 transfusion-dependent thalassemia patients who received a transplant between 1998 and 2015 considering their stem cell source as a comparative variable. In multivariate Cox analysis the survival advantage for bone marrow compared with peripheral blood was not significant after adjusting for sex, age, and hepatic fibrosis presence. Rejection incidence was significantly lower in patients who used peripheral blood as their graft source. Acute and chronic graft-versus-host disease were more frequent in peripheral blood transplants, but the difference was not statistically significant. This study shows that peripheral blood could be an alternative stem cell source in patients undergoing allogeneic HSCT for thalassemia.
  • Identifier: System Number: ETOCvdc_100074765895.0x000001; Journal ISSN: 1083-8791; 10.1016/j.bbmt.2018.09.026
  • Publication Date: 2019
  • Physical Description: Electronic
  • Shelfmark(s): 2087.013000
  • UIN: ETOCvdc_100074765895.0x000001

Searching Remote Databases, Please Wait